|Articles|January 19, 2021
Parenteral Subvisible Particle Testing
Author(s)Entegris
This paper details various USP subvisible particulate tests used to assure the minimization of particle counts in intravenous injections and the requirements and technologies used to meet them.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
2
Industry Experts Probe CNPV Impacts: Part II
3
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
4
METHONOVA™: Enhancing Cell Culture Growth and Productivity with High Purity Methylcellulose
5
